Quanterix Past Earnings Performance
Past criteria checks 0/6
Quanterix's earnings have been declining at an average annual rate of -15.6%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 19.7% per year.
Key information
-15.6%
Earnings growth rate
-3.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 19.7% |
| Return on equity | -9.3% |
| Net Margin | -26.4% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues
Apr 14
Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business
Apr 05Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Mar 03Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation
Oct 12We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate
Jun 12We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth
Feb 10Quanterix Corporation: Selling For Less Than Cash Value
Sep 28We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth
Sep 23Quanterix stock gains after insider buys reported by CEO and CFO
Aug 17We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Mar 28Is Quanterix (NASDAQ:QTRX) A Risky Investment?
Feb 21Revenue & Expenses BreakdownBeta
How Quanterix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 122 | -32 | 90 | 25 |
| 30 Sep 23 | 117 | -39 | 87 | 23 |
| 30 Jun 23 | 112 | -66 | 84 | 23 |
| 31 Mar 23 | 104 | -85 | 88 | 24 |
| 31 Dec 22 | 106 | -97 | 92 | 26 |
| 30 Sep 22 | 110 | -98 | 102 | 28 |
| 30 Jun 22 | 111 | -79 | 105 | 28 |
| 31 Mar 22 | 113 | -66 | 99 | 28 |
| 31 Dec 21 | 111 | -58 | 92 | 28 |
| 30 Sep 21 | 106 | -47 | 83 | 26 |
| 30 Jun 21 | 110 | -30 | 72 | 25 |
| 31 Mar 21 | 98 | -30 | 65 | 23 |
| 31 Dec 20 | 86 | -32 | 60 | 20 |
| 30 Sep 20 | 76 | -33 | 55 | 18 |
| 30 Jun 20 | 60 | -45 | 54 | 17 |
| 31 Mar 20 | 60 | -43 | 53 | 17 |
| 31 Dec 19 | 57 | -41 | 50 | 16 |
| 30 Sep 19 | 52 | -39 | 47 | 16 |
| 30 Jun 19 | 47 | -37 | 43 | 16 |
| 31 Mar 19 | 42 | -34 | 38 | 16 |
| 31 Dec 18 | 38 | -32 | 34 | 16 |
| 30 Sep 18 | 33 | -30 | 29 | 16 |
| 30 Jun 18 | 28 | -30 | 25 | 16 |
| 31 Mar 18 | 25 | -31 | 22 | 16 |
| 31 Dec 17 | 23 | -31 | 20 | 16 |
| 30 Sep 17 | 23 | -31 | 17 | 19 |
| 30 Jun 17 | 21 | -30 | 16 | 18 |
| 31 Mar 17 | 19 | -30 | 14 | 18 |
| 31 Dec 16 | 18 | -28 | 12 | 17 |
| 31 Dec 15 | 12 | -20 | 10 | 10 |
Quality Earnings: QTRX is currently unprofitable.
Growing Profit Margin: QTRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QTRX is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.
Accelerating Growth: Unable to compare QTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QTRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: QTRX has a negative Return on Equity (-9.32%), as it is currently unprofitable.